ReviewACS chemical neuroscience2012
"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.
Review in ACS chemical neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06040164 (Molecular Study of Oral Dysbacteriosis in People With Prediabetes and Diabetes), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular Study of Oral Dysbacteriosis in People With Prediabetes and Diabetes
Who cites it
30 citing papers in PubMed, 73 citations in OpenAlex.
- The endocannabinoid anandamide mediates anti-inflammatory effects through activation of NR4A nuclear receptors.British journal of pharmacology · 2025Article
- Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.Brain sciences · 2022Review
- Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery.International journal of molecular sciences · 2022Review
- The role of dopamine and endocannabinoid systems in prefrontal cortex development: Adolescence as a critical period.Frontiers in neural circuits · 2022Review
- Endocannabinoids in immune regulation and immunopathologies.Immunology · 2021Review
- Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CBPharmacological reports : PR · 2021Review
- Non-opioid Analgesics and the Endocannabinoid SystemBalkan medical journal · 2020Article
- Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling.Journal of lipid research · 2020Article
- Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial.Cannabis and cannabinoid research · 2019Article
- Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.Nature reviews. Cardiology · 2018Review
- Molecular Understanding of the Activation of CB1 and Blockade of TRPV1 Receptors: Implications for Novel Treatment Strategies in Osteoarthritis.International journal of molecular sciences · 2018Article
- Changes in Monoaminergic Neurotransmission in an Animal Model of Osteoarthritis: The Role of Endocannabinoid Signaling.Frontiers in molecular neuroscience · 2018Article
- The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.European journal of rheumatology · 2017Review
- Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Spatial Distribution of the Cannabinoid Type 1 and Capsaicin Receptors May Contribute to the Complexity of Their Crosstalk.Scientific reports · 2016Article
- A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.ChemMedChem · 2016Review
- Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.European journal of medicinal chemistry · 2016Article
- Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation.Current neuropharmacology · 2016Review
- Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management.Frontiers in pharmacology · 2016Review
- Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Redundancy of metabolic pathways and molecular targets is a typical feature of all lipid mediators, and endocannabinoids, which were originally defined as endogenous agonists at cannabinoid CB(1) and CB(2) receptors, are no exception. In particular, the two most studied endocannabinoids, anandamide and 2-arachidonoylglycerol, are inactivated through alternative biochemical routes, including hydrolysis and oxidation, and more than one enzyme might be used even for the same type of inactivating reaction. These enzymes also recognize as substrates other concurrent lipid mediators, whereas, in turn, endocannabinoids might interact with noncannabinoid receptors with subcellular distribution and ultimate biological actions either similar to or completely different from those of cannabinoid receptors. Even splicing variants of endocannabinoid hydrolyzing enzymes, such as FAAH-1, might play distinct roles in endocannabinoid inactivation. Finally, the products of endocannabinoid catabolism may have their own targets, with biological roles different from those of cannabinoid receptors. These peculiarities of endocannabinoid signaling have complicated the use of inhibitors of its inactivation mechanisms as a safer and more efficacious alternative to the direct targeting of cannabinoid receptors for the treatment of several pathological conditions, including pain. However, new strategies, including the rediscovery of "dirty drugs", and the use of certain natural products (including non-THC cannabis constituents), are emerging that might allow us to make a virtue of necessity and exploit endocannabinoid redundancy to develop new analgesics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.